Posts Tagged ‘sida’

Categories

Posted in:

Thursday November 30th, 2017

IDIBAPS hosts the annual meeting of the European AIDS Vaccine Initiative (EAVI2020)

At the beginning of November, scientists from 22 institutions in Europe, Australia, Canada and the United States, which are part of the European AIDS Vaccine Initiative 2020 (EAVI2020), met in Barcelona to analyze the latest advances in the development of an effective vaccine against HIV within the framework of the European Research and Development Program Horizon 2020. The three Spanish centers participating in this consortium are the IDIBAPS, organizer of the meeting, the IrsiCaixa AIDS Research Institute and the Institute of Health Carlos III. In the context of the meeting a photo exhibition entitled “The development of an HIV vaccine in photos” was presented, with the aim of sharing the scientific advances at the community level. This exhibition can be visited at the Hospital Clínic of Barcelona until February 2018. Read the rest of this entry »

Comments Closed
Thursday November 10th, 2016

Scientists from the European AIDS Vaccine Initiative (EAVI2020) meet in Barcelona to analyze the results of the first year of the consortium

Scientists from 22 institutions in Europe, Australia, Canada and the United States meet in Barcelona on November 10-11 to discuss the trajectory and progress of the European AIDS Vaccine Initiative (EAVI2020). This initiative, funded by the European Commission with 23 million euro, started a year ago to accelerate the development of an effective vaccine against HIV. The three Spanish centers participating in the consortium are the IrsiCaixa AIDS Research Institute, which organizes the meeting in Barcelona, the IDIBAPS and the Institute of Health Carlos III. The participation of IrsiCaixa and IDIBAPS is part of HIVACAT, the Catalan research project for an AIDS vaccine.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Wednesday November 12th, 2014

A study shows that elite controllers have a similar genetic profile to that of HIV-uninfected people

The elite controllers (EC) are those people in whom AIDS does not progress despite being infected with HIV. A study led by the IDIBAPS and published in the PLOS ONE journal focuses on whether these EC have a specific genetic profile, different from other patients with HIV, which allows them to control viremia without the need of antiretroviral therapy. Thus, researchers have identified 23 miRNAs differentially expressed, four of which are over-expressed in EC and people without the disease and another 19 are under-expressed in this population compared to patients with HIV. The study was led by Dr. Mireia Arnedo and Dr. Montserrat Plana, researchers at the IDIBAPS group of Infectious Diseases and AIDS, led by Dr. Josep Maria Gatell. The article’s first author is Dr. Lander Egaña-Gorroño.

Read the rest of this entry »

Comments Closed
Monday December 02nd, 2013

A multimedia activity will help students to understand AIDS

IDIBAPS, in addition to working in disease prevention from a research perspective, is actively involved in activities oriented to society. Recently it published a multimedia activity to understand AIDS better, in collaboration with Ambientech and thanks to the Government of Catalonia’s ACDC 2012 funding for science dissemination. Through this interactive activity (in Spanish and Catalan) high school students, and anyone who wishes it, will learn why it is so difficult to combat the HIV virus, how can we prevent it and discuss about how we do approach its carriers.

Read the rest of this entry »

Comments Closed
Thursday January 17th, 2013

Early treatment for HIV slows damage to immune system and reduces risk of transmission

A 48-week course of antiretroviral medication taken in the early stages of HIV infection slows the damage to the immune system and delays the need for long term treatment, according to research published yesterday in the New England Journal of Medicine. However, the delay was only marginally longer than the time already spent on treatment. The study, the largest clinical trial ever undertaken looking at treating people with recent HIV infection, also suggests that the treatment lowers the amount of virus in the blood for up to sixty weeks after it is stopped, which potentially reduces the risk of onward transmission. The only Spanish participant was the HIV Unit of the Infectious Disease Service from IDIBAPS – Hospital Clínic of Barcelona, lead by Dr. Josep Maria Gatell. Dr. Josep Maria Miró was the Principal Investigator of the team, participated in the study design, the inclusion of participants and is member of the Steering Committee of the SPARTAC trial. Dr. JM Miró is one of the main authors of the article published in New England Journal of Medicine this week.

Read the rest of this entry »

Comments Closed
Thursday December 27th, 2012

Studies from Hospital Clínic and IDIBAPS in the Spanish Science Top5 of the year

2012 is ending, a difficult year also for science due to the crisis affecting much of the world. Despite this, it’s not all are bad news. The spanish researchers continue making relevant contributions to the international scientific scene. The website Materia made a top five of the Spanish scientific initiatives of the past year. In this ranking, there are three studies involving professionals from the Hospital Clínic and the IDIBAPS.

Read the rest of this entry »

Comments Closed
Page 1 of 212